Moleculin Biotech, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for MBRX, updated each market day.
MBRX AI Sentiment
AI sees no strong directional signal for Moleculin Biotech, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Moleculin Biotech, Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Sector
Exchange
Market Cap
$13,607,692
Cap Tier
Employees
17
Headquarters
HOUSTON, TX
Listed Since
June 2, 2016
Website
MBRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MBRX Volatility
Moleculin Biotech, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
